Two β-strands of RAGE participate in the recognition and transport of amyloid-β peptide across the blood brain barrier

Biochemical and Biophysical Research Communications

Volumn 439, Issue 2, 2013, Pages 252-257

  Kim, Sun Jick ^a   Ahn, Jang Won ^a   Kim, Hee ^b   Ha, Hee Jin ^b   Lee, Sang Woo ^b   Kim, Hyun Kuk ^c   Lee, Sangho ^a   Hong, Hyun Seok ^b   Kim, Young Ho ^b   Choi, Cheol Yong ^a  

^a Sungkyunkwan University   (South Korea)

^b Medifron DBT   (South Korea)

^c Advanced Protein Technologies Corp   (South Korea)

Author keywords

Strand; A ; Alzheimer's disease; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA SHEET; BLOOD BRAIN BARRIER; DELETION MUTANT; ENZYME LINKED IMMUNOSORBENT ASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN TRANSPORT; SITE DIRECTED MUTAGENESIS;

Β-STRAND; AΒ; ALZHEIMER'S DISEASE; RAGE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; GENE DELETION; HUMANS; MALE; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; PROTEIN INTERACTION MAPS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, IMMUNOLOGIC;

MUS;

EID: 84884280876     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.08.047     Document Type: Article

References (21)

1. Hardy J. A hundred years of Alzheimer's disease research. Neuron 2006, 52:3-13.
2. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
3. Deane R., Zlokovic B.V. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2007, 4:191-197.
4. Deane R., Wu Z., Zlokovic B.V. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004, 35:2628-2631.
5. Han S.H., Kim Y.H., Mook-Jung I. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol. Cells 2011, 31:91-97.
6. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 1992, 267:14998-15004.
7. Xie J., Reverdatto S., Frolov A., Hoffmann R., Burz D.S., Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products. J. Biol. Chem. 2008, 283:27255-27269.
8. Park H., Adsit F.G., Boyington J.C. The 1.5 A crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J. Biol. Chem. 2010, 285:40762-40770.
9. Koch M., Chitayat S., Dattilo B.M., Schiefner A., Diez J., Chazin W.J., Fritz G. Structural basis for ligand recognition and activation of RAGE. Structure 2010, 18:1342-1352.
10. Matsumoto S., Yoshida T., Murata H., Harada S., Fujita N., Nakamura S., Yamamoto Y., Watanabe T., Yonekura H., Yamamoto H., Ohkubo T., Kobayashi Y. Solution structure of the variable-type domain of the receptor for advanced glycation end products: new insight into AGE-RAGE interaction. Biochemistry 2008, 47:12299-12311.
11. Xue J., Rai V., Singer D., Chabierski S., Xie J., Reverdatto S., Burz D.S., Schmidt A.M., Hoffmann R., Shekhtman A. Advanced glycation end product recognition by the receptor for AGEs. Structure 2011, 19:722-732.
12. Kumano-Kuramochi M., Xie Q., Sakakibara Y., Niimi S., Sekizawa K., Komba S., Machida S. Expression and characterization of recombinant C-terminal biotinylated extracellular domain of human receptor for advanced glycation end products (hsRAGE) in Escherichia coli. J. Biochem. 2008, 143:229-236.
13. Sturchler E., Galichet A., Weibel M., Leclerc E., Heizmann C.W. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J. Neurosci. 2008, 28:5149-5158.
14. Deane R., Singh I., Sagare A.P., Bell R.D., Ross N.T., LaRue B., Love R., Perry S., Paquette N., Deane R.J., Thiyagarajan M., Zarcone T., Fritz G., Friedman A.E., Miller B.L., Zlokovic B.V. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest. 2012, 122:1377-1392.
15. Janciauskiene S., Rubin H., Lukacs C.M., Wright H.T. Alzheimer's peptide Abeta1-42 binds to two beta-sheets of alpha1-antichymotrypsin and transforms it from inhibitor to substrate. J. Biol. Chem. 1998, 273:28360-28364.
16. Janciauskiene S., Eriksson S., Wright H.T. A specific structural interaction of Alzheimer's peptide A beta 1-42 with alpha 1-antichymotrypsin. Nat. Struct. Biol. 1996, 3:668-671.
17. Ma J., Brewer H.B., Potter H. Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. Neurobiol. Aging 1996, 17:773-780.
18. Fraser P.E., Nguyen J.T., McLachlan D.R., Abraham C.R., Kirschner D.A. Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. J. Neurochem. 1993, 61:298-305.
19. Eriksson S., Janciauskiene S., Lannfelt L. Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation. Proc. Natl. Acad. Sci. USA 1995, 92:2313-2317.
20. Chaney M.O., Stine W.B., Kokjohn T.A., Kuo Y.M., Esh C., Rahman A., Luehrs D.C., Schmidt A.M., Stern D., Yan S.D., Roher A.E. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim. Biophys. Acta 2005, 1741:199-205.
21. Yan S.D., Zhu H., Zhu A., Golabek A., Du H., Roher A., Yu J., Soto C., Schmidt A.M., Stern D., Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 2000, 6:643-651.